Several pathways involved in the Stages I and II versus Benign groups comparison would logically inhibit metastases (activation of PTEN and repression of HER-2, STAT3 and EMT), and concordantly, these pathways were not present in the Stage IIIC and IV versus to Benign groups comparison, suggesting that loss of PTEN activation and HER-2, STAT3 and EMT repression are involved in endometrial cancer metastatic progression. The gene discussed is ERBB2; the disease is endometrial cancer.